Analysts
The investment firms and equity analysts listed below provide research reports on IMRIS. Opinions, estimates, forecasts or other analyses, including prior or future IMRIS performance from any source is the opinion of the writer and is theirs alone and does not represent the opinions, estimates or forecasts of IMRIS or its management. The Company does not, by any reference below, imply any endorsement of, or concurrence with, information, conclusions drawn or recommendations offered by property of the author.
IMRIS does not distribute research reports, which are the property of the author.
Doug Loe, PhD, MBA
Analyst – Global Healthcare & Biotechnology
Byron Capital Markets
4 King Street West, Suite 1100
Toronto, Ontario
M5H 1B6
T. 647-426-0472
E. dloe@byroncapitalmarkets.com
Jason R. Mills
Analyst - Life Sciences – Biomedical Devices and Services
Canaccord Genuity
San Francisco, California
T 415.229.7166
E jmills@canaccordgenuity.com
Neil Maruoka
Life Sciences - Biomedical Devices and Services
Canaccord Adams
PO Box 516
161 Bay Street, Suite 3000
Toronto, Ontario
M5J 2S1
T 416.869.3073
E neil.maruoka@canaccordadams.com
Sean D. Lavin
Analyst - Equity Research - Medical Technology
Lazard Capital Markets
30 Rockefeller Plaza
New York, New York 10020
T 212.632.6244
E sean.lavin@lazardcap.com
Alan Ridgeway, Ph.D.
Analyst - Biotech and Health Care
Paradigm Capital
95 Wellington Street West, Suite 2101
Toronto, ON, M5J 2N7
T 416.361.9080
E aridgeway@paradigmcap.com
Douglas Miehm
Biotech & Pharmaceutical Research
RBC Dominion Securities Inc
Royal Bank Plaza
South Tower, 3rd Flr
Toronto, ON, M5J 2W7
T 416.842.7823
E douglas.miehm@rbccm.com